ScholarLens Back to search
2011•Linchuang gandanbing zazhiRequires access

Adefovir plus lamivudine combination therapy in patients with chronic hepatitis B

Sui Yunhua

Open publisher page 0 citations

Abstract

0bjective To evaluate the therapeutic effect and safety of adefovir dipivoxil(ADV)plus lamivudine(LAM)for the treatment of patients with chronic hepatitis B.Methods 34 patients in group A received ADV,while 34 patients in group B received ADV and LAM for 48 weeks.Results At week 12,24 and 48,HBV DNA negative rates in group A and B were 5.9%,26.5%,32.4% and 61.8%,47.1%,82.4%,respectively;HBeAg negative rate were 5.9%,8.8%,17.6% and 20.6%,26.5%,32.4%;ALT normalization rate were 11.8%,35.3%,41.2% and 73.5%,55.9%,88.2%,respectively.Conclusion ADV plus LAM is a safe and effective therapy in patients with CHB.

About this research paper

What this paper is about

0bjective To evaluate the therapeutic effect and safety of adefovir dipivoxil(ADV)plus lamivudine(LAM)for the treatment of patients with chronic hepatitis B.Methods 34 patients in group A received ADV,while 34 patients in group B received ADV and LAM for 48 weeks.Results At week 12,24 and 48,HBV DNA negative rates in group A and B were 5.9%,26.5%,32.4% and 61.8%,47.1%,82.4%,respectively;HBeAg negative rate were 5.9%,8.8%,17.6% and 20.6%,26.5%,32.4%;ALT normalization rate were 11.8%,35.3%,41.2% and 73.5%,55.9%,88.2%,respectively.Conclusion ADV plus LAM is a safe and effective therapy in patients with CHB.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

0bjective To evaluate the therapeutic effect and safety of adefovir dipivoxil(ADV)plus lamivudine(LAM)for the treatment of patients with chronic hepatitis B.Methods 34 patients in group A received ADV,while 34 patients in group B received ADV and LAM for 48 weeks.Results At week 12,24 and 48,HBV DNA negative rates in group A and B were 5.9%,26.5%,32.4% and 61.8%,47.1%,82.4%,respectively;HBeAg negative rate were 5.9%,8.8%,17.6% and 20.6%,26.5%,32.4%;ALT normalization rate were 11.8%,35.3%,41.2% and 73.5%,55.9%,88.2%,respectively.Conclusion ADV plus LAM is a safe and effective therapy in patients with CHB.

Key concepts: Adefovir, Lamivudine, Medicine, Chronic hepatitis, Gastroenterology, Internal medicine, HBeAg, Hepatitis B

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Adefovir plus lamivudine combination therapy in patients with chronic hepatitis B — Research Paper | ScholarLens